Digbi Health is a DNA-based digital therapeutics startup that offers digital care programs based on a user’s genetic risk and gut-microbiome to manage various illnesses such as inflammatory digestive disorders, diabetes, obesity, and skin diseases. The two main programs offered by the company are Digbi Control for weight loss and Digbi Digestive for gut health.
Each program which costs USD 190 per annum consists of at-home gut and gene test kits, ongoing monitoring tools via Digbi’s mobile app, health reports, and personalized coaching services. Digbi Health’s clinician network consists of a range of specialties, such as bariatric surgeons, internal medicine, family medicine, lifestyle, chiropractitioners, and nutritional experts.
Founded in 2018, California-based Digbi’s geographical presence spans across the US, India, and Philippines. The company also operates a B2B model, partnering with healthcare providers and enterprises including Stanford Health Care, Centers for Disease Control and Prevention (CDC), UCLA Health, Solera, and HIMSS. In March 2021, Digbi Health concluded a Series A funding round that brought the company’s cumulative funds to USD 13.9 million.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.